Titan Initiates Confirmatory Phase 3 Study Of Probuphine(R) In The Treatment Of Opioid Addiction

Titan Pharmaceuticals, Inc. (Pink Sheets: TTNP) announced the initiation of a randomized, placebo and active controlled, multi-center Phase 3 clinical study of Probuphine in the treatment of opioid addiction. This confirmatory Phase 3 study will be conducted at approximately 23 sites in the United States and randomize approximately 250 patients into three arms: Probuphine (100 patients), Suboxone┬« (100 patients) and placebo (50 patients). The Probuphine and placebo arms will be double blinded, while the Suboxone arm will be open-label… (Source: Health News from Medical News Today)